Comparison · Updated
CJC-1295 No DAC VS Sermorelin
Short answer
Sermorelin has stronger published evidence than CJC-1295 No DAC: tier S (Approved) vs tier C (Animal data).
CJC-1295 No DAC is not FDA-approved; Sermorelin was FDA-approved (Geref, 1997) and later discontinued.
Both are prohibited in sport by WADA under section S2.
01
Side by side
| Field | CJC-1295 No DAC | Sermorelin |
|---|---|---|
| Evidence tier | C Tier C · Animal data | S Tier S · Approved |
| Tier rationale | Published data are mostly preclinical; no completed human trials of this compound were found. | Previously FDA-approved (Geref) for diagnosis and treatment of GH deficiency in children; withdrawn from the market in 2008 for commercial reasons. |
| FDA status | Not approved | Approved 1997, later discontinued GerefApproved for pediatric GH deficiency; discontinued 2008, not for safety reasons. |
| Other approvals | None listed | None listed |
| WADA | Prohibited · S2Peptide hormones, growth factors, related substances and mimetics | Prohibited · S2Peptide hormones, growth factors, related substances and mimetics |
| Family | GH & Growth | GH & Growth |
| Residues | Not on file | Not on file |
| Molecular weight | Not on file | Not on file |
| Formula | Not on file | Not on file |
| Discovered | Not on file | Not on file |
| Routes studied | Subcutaneous, Intramuscular | Subcutaneous, Intramuscular |
| Mechanism | CJC-1295 no DAC (modified GRF 1-29) binds the GHRH receptor on pituitary somatotrophs, stimulating GH release via adenylyl cyclase/cAMP signaling. Without the DAC moiety it has a half-life of approximately 30 minutes, producing a sharp GH pulse that closely mimics the natural pulsatile secretion pattern. | Sermorelin (GHRH 1-29) is the biologically active N-terminal fragment of endogenous GHRH. It binds the GHRH receptor on anterior pituitary somatotrophs and activates cAMP/PKA signaling to promote GH gene transcription and pulsatile GH release. |
| Safety notes | Well-tolerated in clinical settings. | Previously FDA-approved (Geref) with a well-established safety record. |
| Cited studies | 1 study | 0 studies |
02
Questions
- Which has stronger evidence, CJC-1295 No DAC or Sermorelin?
- Sermorelin has stronger published evidence than CJC-1295 No DAC: tier S (Approved) vs tier C (Animal data). CJC-1295 No DAC: Published data are mostly preclinical; no completed human trials of this compound were found. Sermorelin: Previously FDA-approved (Geref) for diagnosis and treatment of GH deficiency in children; withdrawn from the market in 2008 for commercial reasons. Tiers rate the strength of published evidence, not effectiveness.
- Is CJC-1295 No DAC FDA-approved?
- CJC-1295 No DAC is not FDA-approved.
- Is Sermorelin FDA-approved?
- Sermorelin was FDA-approved (Geref, 1997) and later discontinued. Approved for pediatric GH deficiency; discontinued 2008, not for safety reasons.
- Are CJC-1295 No DAC and Sermorelin banned in sport?
- Both are prohibited in sport by WADA under section S2.
- How do CJC-1295 No DAC and Sermorelin work?
- CJC-1295 no DAC (modified GRF 1-29) binds the GHRH receptor on pituitary somatotrophs, stimulating GH release via adenylyl cyclase/cAMP signaling. Sermorelin (GHRH 1-29) is the biologically active N-terminal fragment of endogenous GHRH.